.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Merck
AstraZeneca
QuintilesIMS
Healthtrust
Covington
Mallinckrodt
US Department of Justice
Johnson and Johnson

Generated: September 21, 2017

DrugPatentWatch Database Preview

NORVIR Drug Profile

« Back to Dashboard

What is the patent landscape for Norvir, and what generic Norvir alternatives are available?

Norvir is a drug marketed by Abbvie Inc, Abbvie, and Abbott. and is included in five NDAs. There are eleven patents protecting this drug and two Paragraph IV challenges.

This drug has seventy-one patent family members in thirty-one countries.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ritonavir profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
NORVIR
ritonavir
POWDER;ORAL209512-001Jun 7, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NORVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999► Subscribe► Subscribe
Abbott
NORVIR
ritonavir
CAPSULE;ORAL020680-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010► Subscribe► Subscribe
Abbott
NORVIR
ritonavir
CAPSULE;ORAL020680-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbott
NORVIR
ritonavir
CAPSULE;ORAL020680-001Mar 1, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NORVIR

Drugname Dosage Strength RLD Submissiondate
ritonavirCapsules100 mgNorvir10/31/2012
ritonavirTablets100 mgNorvir12/21/2010

Non-Orange Book Patents for Tradename: NORVIR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,333,990Solid pharmaceutical dosage form► Subscribe
8,377,952Solid pharmaceutical dosage formulation► Subscribe
6,458,818 Pharmaceutical composition► Subscribe
7,659,405Polymorph of a pharmaceutical► Subscribe
7,183,416Polymorph of a pharmaceutical► Subscribe
6,894,171 Polymorph of a pharmaceutical► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
9,255,092Polymorph of a pharmaceutical► Subscribe
8,025,899Solid pharmaceutical dosage form► Subscribe
6,521,651 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NORVIR

Country Document Number Estimated Expiration
Japan2008531565► Subscribe
European Patent Office0871465► Subscribe
Japan2007291131► Subscribe
Georgia, Republic ofP20105083► Subscribe
Portugal2295052► Subscribe
Eurasian Patent Organization014446► Subscribe
Mexico9710403► Subscribe
Taiwan200716119► Subscribe
Australia722812► Subscribe
Japan5087409► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NORVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/044United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
0674513Switzerland► SubscribePRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
00060Netherlands► SubscribePRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Julphar
US Army
Accenture
Healthtrust
Baxter
Argus Health
Farmers Insurance
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot